| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/16/2004 | DE10309353A1 Composition for oral electrolyte and liquid replacement comprises sodium ions derived from the sodium salt of an organic acid |
| 09/16/2004 | DE10308864A1 Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung New brewing process, thus brewed beer and its use |
| 09/16/2004 | DE10307928A1 Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen Using 1- (2-chloroethyl) -1-nitroso-3- (2-hydroxyethyl) -urea for the treatment of pancreatic cancer, soft tissue sarcoma, testicular cancer, lymphoma, thymoma, Wilms tumors, renal carcinomas, melanomas, lung tumors, intracerebral metastasis, tumors in head and neck, and breast carcinomas |
| 09/16/2004 | DE10297018T5 Depotmikrokügelchen für die Injektion von Huperzin-A-Verbindungen Depot microspheres for injection of Huperzine A compounds |
| 09/16/2004 | CA2796381A1 Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| 09/16/2004 | CA2547939A1 Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof |
| 09/16/2004 | CA2518218A1 Tetrazole and oxadiazolone substituted .beta.-amino acid derivatives |
| 09/16/2004 | CA2518199A1 Pharmaceutical preparations containing thiazolidinediones showing new therapeutic indications |
| 09/16/2004 | CA2518193A1 Use of ep2 selective receptor agonists in medical treatment |
| 09/16/2004 | CA2518133A1 Therapeutic agents for drug/substance dependence |
| 09/16/2004 | CA2518100A1 Use of non-immunosuppressive pipecolic acid derivatives for inducing chondrogenic differentiation |
| 09/16/2004 | CA2518094A1 Anaplastic lymphoma kinase assay, reagents and compositions thereof |
| 09/16/2004 | CA2517974A1 Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1 |
| 09/16/2004 | CA2517959A1 Expansion of renewable stem cell populations using modulators of pi 3-kinase |
| 09/16/2004 | CA2517929A1 Novel-chemical entities and methods for their use in treatment of metabolic disorders |
| 09/16/2004 | CA2517886A1 Diphenylethylene compounds and uses thereof |
| 09/16/2004 | CA2517850A1 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent |
| 09/16/2004 | CA2517844A1 Quinazolines useful as modulators of ion channels |
| 09/16/2004 | CA2517537A1 Potassium taurate bicarbonate and ascorbate complexes |
| 09/16/2004 | CA2517528A1 Prophylactic treatment of uv-induced epidermal neoplasia |
| 09/16/2004 | CA2517525A1 Posh interacting proteins and related methods |
| 09/16/2004 | CA2517523A1 Substituted thiophenes with antibacterial activity |
| 09/16/2004 | CA2517461A1 Pyridinium salts, compounds and methods of use |
| 09/16/2004 | CA2517355A1 Resonance modulator for diagnosis and therapy |
| 09/16/2004 | CA2517287A1 Regulation of t cells by lag-3 (cd223) |
| 09/16/2004 | CA2517166A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists |
| 09/16/2004 | CA2517145A1 Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 09/16/2004 | CA2517101A1 A modified oligonucleotide for inhibition of growth hormone receptor expression |
| 09/16/2004 | CA2517085A1 Adiponectin expression promoter |
| 09/16/2004 | CA2516931A1 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
| 09/16/2004 | CA2516629A1 Compositions and methods for preventing and treating endotoxin-related diseases and conditions |
| 09/16/2004 | CA2516624A1 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders |
| 09/16/2004 | CA2516500A1 Regulation of mammalian hair growth |
| 09/16/2004 | CA2516353A1 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor |
| 09/16/2004 | CA2516078A1 Catechol compositions and use thereof |
| 09/16/2004 | CA2515328A1 Use of omega-3-fatty acids in the treatment of diabetic patients |
| 09/16/2004 | CA2515098A1 Invisible patch for active agent controlled delivery |
| 09/16/2004 | CA2514848A1 Use of adenosine receptor agonists in therapy |
| 09/16/2004 | CA2514733A1 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| 09/16/2004 | CA2514098A1 Compounds for the treatment of pain |
| 09/15/2004 | EP1457499A1 Inhibitors of extracellular Hsp90 |
| 09/15/2004 | EP1457495A1 Adenosine A1 receptor agonists |
| 09/15/2004 | EP1457492A1 Crystals of taxane derivative and process for their production |
| 09/15/2004 | EP1457490A1 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 09/15/2004 | EP1457488A1 Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity |
| 09/15/2004 | EP1457485A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them |
| 09/15/2004 | EP1457256A1 Adsorbent for phosphoric acid |
| 09/15/2004 | EP1457213A1 Anthelmintic resinates and a method for their preparation |
| 09/15/2004 | EP1457208A1 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
| 09/15/2004 | EP1457207A1 Solid compositions containng compounds unstable to oxygen and method for stabilization thereof |
| 09/15/2004 | EP1457206A1 Combined use of a fibrate and orlistat for the treatment of obesity |
| 09/15/2004 | EP1457205A1 Angiogenesis inhibitor |
| 09/15/2004 | EP1457202A2 Topical formulation comprising a NSAID, preferably diclofenac, for alleviating pain/inflammation caused by herpes virus infection |
| 09/15/2004 | EP1456670A2 Methods relating to treatment of atherosclerosis |
| 09/15/2004 | EP1456653A2 Genes encoding g-protein coupled receptors and methods of use therefor |
| 09/15/2004 | EP1456650A2 Gfats as modifiers of the p53 pathway and methods of use |
| 09/15/2004 | EP1456408A2 Susceptibility locus for schizophrenia |
| 09/15/2004 | EP1456403A2 Methods of using 48149, a human aminopeptidase family member |
| 09/15/2004 | EP1456402A2 Means for treatment of atherosclerosis |
| 09/15/2004 | EP1456396A1 Hybrid glycosylated products and their production and use |
| 09/15/2004 | EP1456378A2 Il-17 like molecules and uses thereof |
| 09/15/2004 | EP1456377A2 Syn3 compositions and methods |
| 09/15/2004 | EP1456357A2 Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| 09/15/2004 | EP1456353A2 The use of acyl salicylates as heat shock inducers |
| 09/15/2004 | EP1456351A1 New strain of lactic acid bacterium and edible compositions, drugs and veterinary products containing it |
| 09/15/2004 | EP1456330A2 Functional acylglycerides |
| 09/15/2004 | EP1456246A1 Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use |
| 09/15/2004 | EP1456230A2 Flavivirus ns1 subunit vaccine |
| 09/15/2004 | EP1456221A2 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response |
| 09/15/2004 | EP1456219A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine A2a receptor agonist |
| 09/15/2004 | EP1456214A2 Improvements in pharmaceutical compositions |
| 09/15/2004 | EP1456212A1 6-aminomorphinane derivatives, method for the production and use thereof |
| 09/15/2004 | EP1456211A1 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors |
| 09/15/2004 | EP1456210A1 Pyrazolyl-substituted triazoloquinoxalines |
| 09/15/2004 | EP1456208A1 Pyridoquinoxaline antivirals |
| 09/15/2004 | EP1456207A2 Heterocyclic acridone inhibitors of impdh enzyme |
| 09/15/2004 | EP1456206A1 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| 09/15/2004 | EP1456205A1 Imidazoquinoline derivatives |
| 09/15/2004 | EP1456204A1 Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 09/15/2004 | EP1456203A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 09/15/2004 | EP1456202A1 Benzothiazoles |
| 09/15/2004 | EP1456201A1 Benzhydryl derivatives |
| 09/15/2004 | EP1456200A1 Lactams as tachykinin antagonists |
| 09/15/2004 | EP1456199A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
| 09/15/2004 | EP1456198A1 Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases |
| 09/15/2004 | EP1456197A1 Piperidine-2,6-diones that are heterocyclically substituted in position 3 |
| 09/15/2004 | EP1456196A1 Benzothiophenes as adenosine receptor modulators |
| 09/15/2004 | EP1456193A1 PREPARATION OF TRANS-FUSED 3,3a,8,12b-TETRAHYDRO-2 i H /i -DIBENZO 3,4:6,7]CYCLOHEPTA 1,2-b]FURAN DERIVATIVES |
| 09/15/2004 | EP1456192A1 Deuterated substituted dihydrofuranones and medicaments containing these compounds |
| 09/15/2004 | EP1456189A1 Benzothia(dia)zine derivatives and their use as ampa modulators |
| 09/15/2004 | EP1456188A1 7-amino-benzothiazole derivatives as adenosine receptor ligands |
| 09/15/2004 | EP1456187A1 N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| 09/15/2004 | EP1456186A1 Novel inhibitor compounds specific of secreted non-pancreatic human a sb 2 /sb phospholipase of group ii |
| 09/15/2004 | EP1456184A1 Bis(cyanophenyl)methyl-triazole for use in prevention of breast cancer |
| 09/15/2004 | EP1456182A1 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) |
| 09/15/2004 | EP1456181A1 Methods for preparing sodium-hydrogen exchanger type-1 inhibitors |
| 09/15/2004 | EP1456180A1 3,4-diarylpyrazoles and their use in the therapy of cancer |
| 09/15/2004 | EP1456179A1 Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds |
| 09/15/2004 | EP1456178A1 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| 09/15/2004 | EP1456172A1 Pyrrolidine-2-ones as factor xa inhibitors |